Right now, doctors can’t tell whether women with DCIS will go on to develop breast cancer. This means that, unfortunately, some women with DCIS undergo unnecessary treatment. Find out how Jelle and his team are looking to change this.
Would you like to discover exclusive content from the hottest topics in oncology? Editor, Jade Parker, highlights Oncology Centrals top content in this report.
Researchers from the Dana-Farber Cancer Institute (MA, USA) have conducted the largest genomic analysis of patients with smoldering multiple myeloma –a precursor to multiple myeloma. The results may offer a new insight into the mechanism of multiple myeloma progression.
Researchers at The institute of Cancer Research (London, UK) have identified six genetic changes that increase the risk of developing Hodgkin lymphoma.
A genetics study has unearthed an unexpected new drug target for acute myeloid leukaemia that could open new avenues to develop effective treatments.
A team of scientists have bound gene editing CRISPR/Cas9 to nucleotide aptamers to selectively target and edit osteosarcoma cancer cells.
A new genetic test could help diagnose esophageal cancer up to 8 years before symptoms appear in individuals at a high risk of the disease.
Three single-nucleotide polymorphisms have been identified as viable candidates as biomarkers for the personalized monitoring and treatment of lung cancers.
Researchers from the University of Georgia (GA, USA) have suggested the cause behind an increase in breast cancer genetic testing in the US in 2013.